Novo Nordisk


The fattish obesity opportunity!

22/11/22 -"While diabetes has been Novo’s traditional stronghold, the firm is also the front-runner to grab a big share of the rapidly-growing obesity market. A combination of changing market dynamics, ..."

Pages
66
Language
English
Published on
22/11/22
You may also be interested by these reports :
23/11/22
CFO Roadshow highlights confirm our bullish view on the stock

23/11/22
Destocking in November is far more brutal than expected by EU chemical companies in its 3Q22 conference calls and might trigger inventory ...

22/11/22
While diabetes has been Novo’s traditional stronghold, the firm is also the front-runner to grab a big share of the rapidly-growing obesity market. A ...

18/11/22
After another quarterly performance beat in Q3, Novo remains on track to sustain its exceptional operating momentum. Besides our medium-term ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO